IQVIA Holdings (IQV) AI Stock Analysis

• Market Cap: $31.74B
• Dividend Yield: N/A
• Average Volume (3M): 1.24M
• Price to Earnings (P/E): 27.0
• Beta (1Y): 0.91
• Revenue Growth: 3.53%
• EPS Growth: -10.72%
• Country: US
• Employees: 89,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 2.81
• Shares Outstanding: 170,000,000
• 10 Day Avg. Volume: 1,184,205
• 30 Day Avg. Volume: 1,239,975
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 2.60
• Enterprise Value/Gross Profit: 7.59
• Enterprise Value/Ebitda: 12.19
• 1Y Price Target: $215.08
• Price Target Upside: 15.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 79 Outperform
• Price Target: $221.00 ▲(18.38% Upside)

IQVIA's strong financial performance and positive earnings call insights are the most significant contributors to its overall score. The company's strategic focus on AI and robust revenue growth in key segments bolster its position. While the valuation is relatively high, it reflects confidence in future growth. Technical indicators support a bullish outlook, although the lack of a dividend yield is a minor drawback.

Positive Factors

Strategic Collaboration

This collaboration enhances IQVIA's market reach and innovation capabilities, leveraging its analytics and AI to drive drug development efficiency.

Revenue Growth

Record revenue indicates strong market demand and effective business strategies, supporting long-term growth and competitive positioning.

AI Advancements

AI advancements enhance IQVIA's service offerings, improving efficiency and innovation, thus strengthening its competitive advantage in life sciences.

Negative Factors

Gross Margin Pressure

Sustained margin pressure could impact profitability, limiting financial flexibility and affecting long-term operational efficiency.

R&D Solutions Growth Challenge

Slower growth in R&D Solutions may hinder overall revenue expansion, affecting IQVIA's ability to capitalize on market opportunities.

Elongated Decision Timelines

Prolonged decision timelines can delay project starts, impacting revenue recognition and operational efficiency in the long term.

IQVIA Holdings Business Overview & Revenue Model

Company Description

IQVIA Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. The company operates in two primary segments: Technology & Analytics Solutions and Contract Research Services. IQVIA leverages its extensive healthcare data and insights to help clients accelerate drug development, optimize commercial strategies, and improve patient outcomes. Its core offerings include real-world evidence, clinical trial management, regulatory compliance, and market access solutions.

How the Company Makes Money

IQVIA generates revenue through a combination of service-based contracts and subscription-based solutions. Its key revenue streams include fees from clinical trial management and support services, which involve designing and conducting clinical trials for pharmaceutical and biotechnology companies. Additionally, IQVIA earns revenue from its technology solutions, including data analytics and software platforms that offer insights into healthcare trends and patient populations. Significant partnerships with pharmaceutical companies and healthcare organizations enhance its credibility and market reach, contributing to steady revenue growth. Furthermore, IQVIA's ability to provide integrated solutions across the drug development lifecycle allows it to capture a larger share of the market, driving further earnings.

IQVIA Holdings Financial Statement Overview

Summary

IQVIA Holdings demonstrates strong financial health with consistent revenue and profit growth, efficient operational margins, and solid cash flow generation. While the balance sheet carries substantial liabilities, the company's low debt-to-equity ratio and high ROE mitigate some of the leverage risks.

Income Statement

IQVIA Holdings exhibits strong profitability with a consistent upward trend in revenue and net income. The recent TTM data shows a net profit margin of 7.88% and a gross profit margin of 34.24%, indicating efficient cost management. The revenue growth rate from 2024 to TTM is 1.91%, reflecting steady growth. EBIT and EBITDA margins are robust at 13.87% and 21.39%, respectively, showcasing solid operational performance.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.26, indicating a low reliance on debt. The equity ratio of 20.17% suggests a moderate level of equity financing. Return on equity (ROE) is strong at 21.41%, highlighting efficient use of shareholder funds. However, the overall leverage remains a potential risk with total liabilities significantly outweighing equity.

Cash Flow

The cash flow statements indicate a healthy cash generation capacity with a free cash flow of $2.303 billion in TTM, showing a growth rate of 8.93% from the previous year. The operating cash flow to net income ratio is 2.12, and the free cash flow to net income ratio is 1.86, both suggesting strong cash conversion and liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.70B	15.40B	14.98B	14.41B	13.87B	11.36B
Gross Profit	5.38B	5.38B	5.24B	5.03B	4.64B	3.86B
EBITDA	3.35B	3.45B	3.26B	2.91B	2.77B	2.08B
Net Income	1.24B	1.37B	1.36B	1.09B	966.00M	279.00M
Balance Sheet
Total Assets	28.63B	26.90B	26.68B	25.34B	24.69B	24.56B
Cash, Cash Equivalents and Short-Term Investments	2.19B	1.84B	1.50B	1.31B	1.48B	1.90B
Total Debt	15.70B	14.16B	13.90B	13.01B	12.44B	12.90B
Total Liabilities	22.85B	20.83B	20.57B	19.57B	18.65B	18.28B
Stockholders Equity	5.78B	6.07B	6.11B	5.76B	6.04B	6.00B
Cash Flow
Free Cash Flow	2.01B	2.11B	1.50B	1.59B	2.30B	1.34B
Operating Cash Flow	2.62B	2.72B	2.15B	2.26B	2.94B	1.96B
Investing Cash Flow	-1.56B	-1.44B	-1.60B	-2.01B	-2.10B	-796.00M
Financing Cash Flow	-625.00M	-878.00M	-382.00M	-329.00M	-1.24B	-217.00M

IQVIA Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 186.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IQV, the sentiment is Positive. The current price of 186.69 is below the 20-day moving average (MA) of 187.57, above the 50-day MA of 183.19, and above the 200-day MA of 177.69, indicating a neutral trend. The MACD of 0.92 indicates Positive momentum. The RSI at 50.98 is Neutral, neither overbought nor oversold. The STOCH value of 54.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IQV.

IQVIA Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDP	80 Outperform	13.99B	37.02	242.70%	―	9.94%	25.30%
IQV	79 Outperform	$31.74B	27.04	19.80%	―	3.53%	-10.72%
TMO	78 Outperform	178.47B	27.83	13.03%	0.36%	2.05%	7.03%
ICLR	72 Outperform	13.63B	18.01	8.31%	―	-2.91%	12.92%
DGX	70 Neutral	20.38B	21.54	13.13%	1.70%	12.58%	13.00%
DHR	69 Neutral	138.15B	40.45	6.52%	0.61%	-3.24%	-16.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

IQVIA Holdings Corporate Events

IQVIA Holdings Announces New CFO Appointment

On September 2, 2025, IQVIA Holdings announced the appointment of Michael J. Fedock as Executive Vice President and Chief Financial Officer, effective February 28, 2026. This transition is part of the company’s CFO succession plan, with Fedock succeeding Ronald E. Bruehlman, who will retire and transition to a Senior Advisor role to the CEO. Fedock, with over 25 years of experience in the healthcare industry, has held several senior financial roles within IQVIA since joining in 2016. The transition aims to ensure continuity and support IQVIA’s long-term growth strategy, with Bruehlman having played a crucial role in the company’s transformation and growth since 2011.

IQVIA Holdings Issues $2 Billion in Senior Notes

On June 4, 2025, IQVIA Inc., a subsidiary of IQVIA Holdings Inc., successfully issued and sold $2 billion in 6.250% senior notes due 2032. The proceeds from this offering will be used to repay existing borrowings under the company’s revolving credit facility and cover related fees and expenses, with any remaining funds allocated for general corporate purposes. This financial maneuver is expected to impact the company’s operations by optimizing its debt structure and potentially enhancing its market positioning.